scholarly journals Office blood pressure threshold of 130/80 mmHg better predicts uncontrolled out‐of‐office blood pressure in apparent treatment‐resistant hypertension

2020 ◽  
Author(s):  
Chan Joo Lee ◽  
Jeong‐Ha Ha ◽  
Jang Young Kim ◽  
In‐Cheol Kim ◽  
Sung Kee Ryu ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Office Blood Pressure ◽  
Treatment Resistant ◽  
Pressure Threshold ◽  
Blood Pressure Threshold

scholarly journals Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network

Hypertension ◽  
2013 ◽  
Vol 62 (4) ◽  
pp. 691-697 ◽  
Author(s):  
Brent M. Egan ◽  
Yumin Zhao ◽  
Jiexiang Li ◽  
W. Adam Brzezinski ◽  
Thomas M. Todoran ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Optimal Treatment ◽  
Office Blood Pressure ◽  
Treatment Resistant ◽  
Community Based ◽  
Treatment Regimens ◽  
Practice Network

scholarly journals Improvement of Blood Pressure Control by Adherence Check in Patients With Apparent Treatment-Resistant Hypertension: A Case Series

2020 ◽  
Vol 13 ◽  
pp. 117954762090488
Author(s):  
Keiko Hosohata ◽  
Ayaka Inada ◽  
Saki Oyama ◽  
Takashi Doi ◽  
Iku Niinomi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Antihypertensive Drugs ◽  
Case Series ◽  
Pressure Control ◽  
Supporting Evidence ◽  
Treatment Resistant ◽  
Uncontrolled Blood Pressure ◽  
Important Challenge ◽  
Prescribed Medicines

Adherence to medications is an important challenge while treating chronic disease such as resistant hypertension, which is defined as uncontrolled blood pressure (BP) despite treatment with more than 3 antihypertensive drugs to achieve targets. It is possible that poor adherence is the most significant contributor to rates of pseudo-resistance among treated hypertensive patients. In this report, we describe 4 patients with apparent treatment-resistant hypertension, who received intervention to promote adherence by pharmacists who set the prescribed medicines in a weekly medication calendar and conducted a weekly pill count. The results showed that the intervention of pharmacists to medication adherence improved systolic BP in patients with apparent treatment-resistant hypertension; however, further controlled trials are required to strengthen supporting evidence.

scholarly journals Extracellular vesicles as a novel diagnostic and research tool for patients with HTN and kidney disease

2019 ◽  
Vol 317 (3) ◽  
pp. F641-F647 ◽  
Author(s):  
Uta Erdbrügger ◽  
Thu H. Le
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Kidney Disease ◽  
Extracellular Vesicles ◽  
Organ Damage ◽  
The United States ◽  
End Organ Damage ◽  
Pressure Threshold ◽  
Stage Renal Disease ◽  
Blood Pressure Threshold

Hypertension (HTN) affects one in three adults in the United States and is a major risk factor for cardiovascular disease and kidney failure. There is emerging evidence that more intense blood pressure lowering reduces mortality in patients with kidney disease who are at risk of cardiovascular disease and progression to end-stage renal disease. However, the ideal blood pressure threshold for patients with kidney disease remains a question of debate. Novel tools to more precisely diagnose HTN, tailor treatment, and predict the risk of end-organ damage such as kidney disease are needed. Analysis of circulating and urinary extracellular vesicles (EVs) and their cargo (protein and RNA) has the potential to identify novel noninvasive biomarkers that can also reflect a specific pathological mechanism of different HTN phenotypes. We will discuss the use of extracellular vesicles as markers of HTN severity and explain their profile change with antihypertensive medicine and potential to detect early end-organ damage. However, more studies with enhanced rigor in this field are needed to define the blood pressure threshold to prevent or delay kidney disease progression and decrease cardiovascular risk.

scholarly journals FP092CLINICAL CHARACTERISTICS OF APPARENT TREATMENT-RESISTANT HYPERTENSION IN CHRONIC KIDNEY DISEASE PATIENTS EVALUATED BY 24 HOUR AMBULATORY BLOOD PRESSURE MONITORING

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii97-iii97
Author(s):  
Biljana Gerasimovska Kitanovska ◽  
Stevka Bogdanovska ◽  
Svetlana Pavleska Kuzmanovska ◽  
Vesna Gerasimovska ◽  
Aleksandar Sikole
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Ambulatory Blood Pressure Monitoring ◽  
Ambulatory Blood Pressure ◽  
Resistant Hypertension ◽  
Blood Pressure Monitoring ◽  
Treatment Resistant ◽  
Pressure Monitoring

scholarly journals SUN-228 ACC/AHA BLOOD PRESSURE THRESHOLD AND BURDEN OF HYPERTENSION, AND PREVENTING CHRONIC KIDNEY DISEASE

2019 ◽  
Vol 4 (7) ◽  
pp. S253-S254
Author(s):  
E. Nwankwo ◽  
B.B. Nwankwo ◽  
H. Mamven
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pressure Threshold ◽  
Blood Pressure Threshold

scholarly journals The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study

2018 ◽  
Vol 20 (3) ◽  
pp. 438-446 ◽  
Author(s):  
Marguerite R. Irvin ◽  
John N. Booth ◽  
Mario Sims ◽  
Adam P. Bress ◽  
Marwah Abdalla ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Jackson Heart Study ◽  
Treatment Resistant ◽  
Nocturnal Hypertension ◽  
Heart Study

scholarly journals Effect of Arteriovenous Fistula Creation on Systolic and Diastolic Blood Pressure in Patients With Pre-dialysis Advanced Chronic Kidney Disease

2019 ◽  
Vol 32 (9) ◽  
pp. 858-867 ◽  
Author(s):  
Roy O Mathew ◽  
Jerome Fleg ◽  
Janani Rangaswami ◽  
Bo Cai ◽  
Arif Asif ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Arteriovenous Fistula ◽  
Resistant Hypertension ◽  
Repeated Measures ◽  
Treatment Resistant ◽  
Advanced Chronic Kidney Disease ◽  
Stage Renal Disease ◽  
End Stage

AbstractBACKGROUNDCentral arteriovenous fistula (cAVF) has been investigated as a therapeutic measure for treatment-resistant hypertension in patients without advanced chronic kidney disease (CKD). There is considerable experience with the use of AVF for hemodialysis in patients with end-stage renal disease (ESRD). However, there is sparse data on the blood pressure (BP) effects of an AVF among patients with ESRD. We hypothesized that AVF creation would significantly reduce BP compared with patients who did not have an AVF among patients with ESRD before starting hemodialysis.METHODSBPs were compared during the 12 months before hemodialysis initiation in 399 patients with an AVF or AV graft created and 4,696 patients without either.RESULTSAfter propensity score matching 1:2 ratio (AVF to no AVF), repeated measures analysis of variance revealed significant reductions of –1.7 mm Hg systolic and –3.9 mm Hg diastolic BP 12 months in patients after AVF creation; P = 0.025 and P < 0.001, respectively, compared with those with no AVF.CONCLUSIONSThese findings suggest that AVF creation results in modest BP reduction in patients with pre-dialysis ESRD who require AVF for eventual hemodialysis therapy. Preferential diastolic BP reduction suggests that greater work is needed to characterize the ideal patient subset in which to use cAVF for treatment-resistant hypertension in those without advanced CKD.

Impact of diastolic blood pressure threshold for the young population

2019 ◽  
Vol 37 (3) ◽  
pp. 652-653
Author(s):  
Kei Asayama ◽  
Yuki Kinoshita ◽  
Shinya Watanabe ◽  
Takayoshi Ohkubo ◽  
Takashi Ando ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Young Population ◽  
Pressure Threshold ◽  
Blood Pressure Threshold

Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline

2019 ◽  
Vol 94 (5) ◽  
pp. 776-782 ◽  
Author(s):  
Kershaw V. Patel ◽  
Xilong Li ◽  
Nitin Kondamudi ◽  
Muthiah Vaduganathan ◽  
Beverley Adams-Huet ◽  
...  
Keyword(s):  
United States ◽  
Blood Pressure ◽  
High Blood Pressure ◽  
Resistant Hypertension ◽  
The United States ◽  
Treatment Resistant
Sign in / Sign up

Export Citation Format

Share Document